By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Syros Pharmaceuticals 

480 Arsenal Street
Suite 130
Watertown  Massachusetts  02472  U.S.A.
Phone: 617-744-1340 Fax: n/a


We are a therapeutics company passionately committed to applying our scientific leadership in the emerging field of gene control to transform the lives of patients with cancer and other diseases.

Founded by world-leading experts in gene regulation, and led by a seasoned management team, Syros is focused on developing new medicines that control genes that cause disease. Central to our approach is a proprietary drug development platform of integrated gene control assay technologies, computational biology, chemistry, and deep biologic insights that gives us an unprecedented understanding of and control over gene regulation. Our pioneering research and drug development capabilities provide us with the distinctive ability to identify new, important disease and patient-targeted gene control medicines.

Key Statistics

Ownership: Private

Web Site: Syros Pharmaceuticals


Company News
Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing 1/13/2016 10:26:00 AM
Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity Of First-In-Class Selective CDK7 Inhibitor In Models Of Acute Leukemias 12/7/2015 1:51:04 PM
Syros Pharmaceuticals Appoints David A. Roth, M.D., As Chief Medical Officer 12/7/2015 11:00:19 AM
Syros Pharmaceuticals Announces Issuance Of U.S. Patents Related To Its Gene Control Drug Discovery And Development Platform 11/10/2015 11:15:51 AM
Syros Pharmaceuticals To Present Preclinical Data On First-In-Class Selective CDK7 Inhibitor Program At American Society of Hematology Annual Meeting 11/5/2015 12:18:57 PM
Syros Pharmaceuticals Appoints Industry Leader Marsha H. Fanucci To Its Board Of Directors 10/19/2015 10:36:34 AM
Syros Pharmaceuticals Announces New Publication Highlighting The Strong Potential Of CDK7 Inhibition In Difficult-To-Treat Cancer 9/25/2015 10:48:30 AM
Syros Pharmaceuticals Licenses Clinical-Stage Rara Agonist To Develop And Commercialize For Genomically-Defined Cancer Populations Identified By Gene Control Platform 9/24/2015 10:39:19 AM
Syros Pharmaceuticals Appoints Kyle Kuvalanka As Chief Operating Officer 9/21/2015 11:11:48 AM
Syros Pharmaceuticals To Participate In September Investor Conferences 9/8/2015 11:22:09 AM